MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Status:
Withdrawn
Trial end date:
2022-11-11
Target enrollment:
Participant gender:
Summary
This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy
treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors.
Subjects will received Gemcitabine, Abraxane and PEGPH20.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania